Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 ...Middle East

LUND, Sweden, Dec. 28, 2020 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial Authorization) application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting...

Hence then, the article about alligator bioscience submits cta for the mitazalimab phase ii study optimize 1 was published today ( Monday 28/12/2020 - 02:01 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 )

Also on site :

• STAG INDUSTRIAL TO REPORT FIRST QUARTER 2026 RESULTS
• Dodgers Claim Grant Holman From D-Backs
• Trump economic approval tanks